Nektar Therapeutics Stock Performance
| NKTR Stock | USD 0.86 0.01 1.15% |
Nektar Therapeutics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.56, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nektar Therapeutics will likely underperform. Nektar Therapeutics right now secures a risk of 5.69%. Please verify Nektar Therapeutics jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Nektar Therapeutics will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nektar Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable basic indicators, Nektar Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Last Split Factor 2:1 | Last Split Date 2000-08-23 |
1 | Disposition of 33402 shares by Mark Wilson of Nektar Therapeutics at 0.9 subject to Rule 16b-3 | 12/23/2024 |
2 | Disposition of 16560 shares by Mark Wilson of Nektar Therapeutics at 0.89 subject to Rule 16b-3 | 12/24/2024 |
3 | Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis | 02/10/2025 |
4 | Acquisition by Whitfield Roy A of 20400 shares of Nektar Therapeutics at 3.47 subject to Rule 16b-3 | 02/26/2025 |
5 | Nektar Therapeutics Buy Rating Reiterated at HC Wainwright | 02/28/2025 |
6 | Nektar Therapeutics Non-GAAP EPS of 0.15 beats by 0.35, revenue of 29.17M misses by | 03/12/2025 |
7 | Nektar Reports Q4 Earnings What Key Metrics Have to Say | 03/13/2025 |
8 | Nektar Therapeutics Full Year 2024 Earnings EPS Beats Expectations, Revenues Lag | 03/14/2025 |
9 | Discretionary transaction by Deep Track Capital, Lp of tradable shares of Nektar Therapeutics subject to Rule 16b-3 | 03/18/2025 |
| Begin Period Cash Flow | 35.3 M |
Nektar |
Nektar Therapeutics Relative Risk vs. Return Landscape
If you would invest 90.00 in Nektar Therapeutics on December 23, 2024 and sell it today you would lose (4.00) from holding Nektar Therapeutics or give up 4.44% of portfolio value over 90 days. Nektar Therapeutics is currently generating 0.0789% in daily expected returns and assumes 5.6898% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Nektar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nektar Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nektar Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nektar Therapeutics, and traders can use it to determine the average amount a Nektar Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0139
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | NKTR | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.69 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Nektar Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nektar Therapeutics by adding it to a well-diversified portfolio.
Nektar Therapeutics Fundamentals Growth
Nektar Stock prices reflect investors' perceptions of the future prospects and financial health of Nektar Therapeutics, and Nektar Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nektar Stock performance.
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.21) % | ||||
| Operating Margin | (0.85) % | ||||
| Current Valuation | 9.04 M | ||||
| Shares Outstanding | 186.1 M | ||||
| Price To Earning | 8.02 X | ||||
| Price To Book | 2.66 X | ||||
| Price To Sales | 1.63 X | ||||
| Revenue | 98.43 M | ||||
| Gross Profit | 67.74 M | ||||
| EBITDA | (86.7 M) | ||||
| Net Income | (118.96 M) | ||||
| Cash And Equivalents | 546.39 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 102.56 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 7.14 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (175.71 M) | ||||
| Earnings Per Share | (0.58) X | ||||
| Market Capitalization | 160.74 M | ||||
| Total Asset | 303.85 M | ||||
| Retained Earnings | (3.6 B) | ||||
| Working Capital | 199.89 M | ||||
| Current Asset | 350.05 M | ||||
| Current Liabilities | 61.25 M | ||||
About Nektar Therapeutics Performance
Assessing Nektar Therapeutics' fundamental ratios provides investors with valuable insights into Nektar Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nektar Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 144.34 | 141.06 | |
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.43) | (0.46) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (1.96) | (2.06) |
Things to note about Nektar Therapeutics performance evaluation
Checking the ongoing alerts about Nektar Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nektar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nektar Therapeutics had very high historical volatility over the last 90 days | |
| Nektar Therapeutics has some characteristics of a very speculative penny stock | |
| Nektar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 98.43 M. Net Loss for the year was (118.96 M) with profit before overhead, payroll, taxes, and interest of 67.74 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (175.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nektar Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Nektar Therapeutics Full Year 2024 Earnings EPS Beats Expectations, Revenues Lag |
- Analyzing Nektar Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nektar Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nektar Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nektar Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nektar Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nektar Therapeutics' stock. These opinions can provide insight into Nektar Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.